Key facts
MK-677 (Ibutamoren) is a growth hormone secretagogue that increases ghrelin and IGF-1 without affecting cortisol. It is not approved for cancer and is not studied as a cancer treatment in humans. Some laboratory studies suggest pathways that could theoretically influence cancer biology, but these findings do not establish risk or benefit in people with cancer. This overview summarizes current evidence, mechanisms, and safety considerations to help patients and clinicians discuss MK-677 with their care team.
What is MK-677 and how does it work
MK-677, also known as Ibutamoren, is a small-molecule compound that acts as a growth hormone secretagogue receptor agonist. It binds to the ghrelin receptor (GHSR-1a) in the brain, stimulating the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Unlike GH-releasing peptides, MK-677 does not significantly affect cortisol, insulin sensitivity, or glucose homeostasis in most studies at approved ranges. Approved uses do not include cancer, and prescribing it for cancer is considered off-label.
How MK-677 affects growth hormone and IGF-1
By activating GHSR-1a, MK-677 promotes pulsatile GH secretion from the pituitary, which in turn increases hepatic IGF-1 production. Higher IGF-1 can drive cell proliferation and survival in some tissues, which is why researchers investigate its role in physiology and disease. In healthy adults, MK-677 raises IGF-1 into the high-normal or mildly elevated range for age without changing GH-binding protein in a clinically adverse way for most people.
Why MK-677 is studied in relation to cancer
Cancer biology is sensitive to hormonal and growth factors, so agents that alter GH and IGF-1 are of interest. IGF-1 and its receptor (IGF-1R) can promote proliferation and survival in certain tumors in laboratory settings, which underpins the theoretical concern and research interest. MK-677 increases IGF-1, prompting studies of its implications for cancer risk and supportive care. No robust clinical data show that MK-677 prevents, treats, or worsens cancer outcomes in humans.
Tumor types and observed effects in preclinical models
In cell and animal models, IGF-1 signaling has been associated with the growth of several tumor types, including breast, prostate, colorectal, and lung cancers. Some experiments show that blocking IGF-1R can slow tumor growth in models, while others report context-dependent effects. MK-677 has not been tested in cancer patients for tumor impact; findings from non-cancer contexts should not be interpreted as treatment effects.
Human evidence, safety considerations, and side effects
In non-cancer clinical trials, MK-677 increases lean mass, muscle strength, and bone mineral density, while also raising appetite and potential fluid retention. Common side effects include increased hunger, edema, joint pain, and transient increases in blood glucose in susceptible individuals. Long-term safety in people with active cancer or a history of cancer is not established. Because MK-677 can increase IGF-1, clinicians often recommend caution in individuals with hormonally driven cancers.
Common adverse effects and lab changes
- Increased appetite and weight gain
- Peripheral edema and fluid retention
- Joint and muscle pain
- Possible worsening of insulin resistance in predisposed individuals
- Potential influence on tumor-promoting pathways in theory, but human data are lacking
Current clinical guidance and research status
MK-677 is not approved for cancer treatment or cancer-related indications. Major guidelines do not recommend it for oncology use. Research is limited to small exploratory studies and mechanistic investigations; large, high-quality trials in cancer populations are absent. Patients should avoid using MK-677 without medical supervision, especially with active or prior cancer, and clinicians should consider tumor type, hormone receptor status, and overall risk before considering use.
Clinical recommendations summary
| Attribute | Verified Detail | Source Type |
|---|---|---|
| MK-677 cancer indication | Not approved; off-label only | Regulatory label |
| Evidence level in cancer | Preclinical and mechanistic; no human treatment data | Literature review |
| Key safety concern | Increased IGF-1; caution with hormonally sensitive tumors | Clinical guidance |
| Recommended use in cancer | Not recommended; consult oncology team | Expert consensus |
| Common side effects | Edema, increased appetite, joint pain, possible glucose changes | Clinical trial data |
Patient questions to ask a clinician
If you are considering MK-677 while living with or beyond cancer, discuss these points with your care team:
- How might increased IGF-1 interact with my tumor type or treatment?
- What monitoring is needed for glucose, lipids, and fluid balance?
- Are there interactions with my current medications or therapies?
- What are the realistic expectations and risks of using MK-677 outside of approved indications?
- Should I avoid MK-677 during or after certain cancer treatments (e.g., chemotherapy, immunotherapy)?
Bottom line
MK-677 raises IGF-1 and is not a proven cancer therapy; evidence in humans is lacking. Theoretical concerns exist due to IGF-1’s role in cell growth, but clinical relevance to cancer outcomes is unknown. People with cancer should discuss risks, monitoring, and alternatives with their oncology team before using MK-677. This overview is for educational purposes and does not replace personalized medical advice.